wire - news in brief


Category



Results 251 - 300 of 300.

Medicine/Pharmacology - Life Sciences
10.11.2017
Use of antibiotics - only if necessary
Bern, 10.11.2017 - Spearheading the fight against antimicrobial resistance, the World Health Organization (WHO) launched its Antibiotic Awareness Week.
Medicine/Pharmacology
10.11.2017
Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness
Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness Brolucizumab, the first and only anti-VEGF to maintain a majority of patients on a 12-week treatment schedule immediately following loading phase in Phase III trials, met primary endpoint of non-inferiority vs aflibercept   Significantly fewer brolucizumab patients showed signs o
Medicine/Pharmacology - Life Sciences
08.11.2017
Novartis reports positive results from Phase III trial of Kisqali (ribociclib) combination therapy in premenopausal women with HR+/HER2- advanced or metastatic breast cancer
Novartis reports positive results from Phase III trial of Kisqali (ribociclib) combination therapy in premenopausal women with HR+/HER2- advanced or metastatic breast cancer MONALEESA-7 met primary e
Chemistry - Environment/Sustainable Development
07.11.2017
Wood goes high-tech
Wood goes high-tech
Wood could potentially replace petrol in chemistry and concrete in construction, according to studies conducted under the National Research Programme "Resource Wood".
Chemistry - Environment/Sustainable Development
07.11.2017
Wood goes high-tech
Wood goes high-tech
Wood could potentially replace petrol in chemistry and concrete in construction, according to studies conducted under the National Research Programme "Resource Wood".
Physics/Materials Science
07.11.2017
Muscles out of a spray can
Muscles out of a spray can
An artificial heart would be an absolute lifesaver for people with cardiac failure. However, to recreate the complex organ in the laboratory, one would first need to work out how to grow multi-layered, living tissues.
Medicine/Pharmacology - Life Sciences
07.11.2017
FDA approves Zelboraf (vemurafenib) for Erdheim-Chester disease with BRAF V600 mutation
FDA approves Zelboraf (vemurafenib) for Erdheim-Chester disease with BRAF V600 mutation Zelboraf is the first FDA-approved treatment for Erdheim-Chester disease (ECD), a rare blood disease Approval based on data from a basket study, which enrolls participants across multiple diseases based predominantly on genetic profile Roche announced today that the US Food and Drug Administration (FDA) has approved Zelboraf (vemurafenib) for Erdheim-Chester disease (ECD) with BRAF V600 mutation.
Medicine/Pharmacology
07.11.2017
Novartis announces study data demonstrating Cosentyx reduced signs and symptoms of psoriatic arthritis while inhibiting progression of joint structural damage
Novartis announces study data demonstrating Cosentyx reduced signs and symptoms of psoriatic arthritis while inhibiting progression of joint structural damage Structural joint damage in psoriatic art
Medicine/Pharmacology - Life Sciences
06.11.2017
Novartis reaches another regulatory milestone for CTL019 (tisagenlecleucel) with submission of its MAA* to EMA for children, young adults with r/r B-cell ALL and adult patients with r/r DLBCL
Novartis reaches another regulatory milestone for CTL019 (tisagenlecleucel) with submission of its MAA* to EMA for children, young adults with r/r B-cell ALL and adult patients with r/r DLBCL Applica
Medicine/Pharmacology
06.11.2017
Novartis seeks leadership with Cosentyx showing no radiographic progression in ankylosing spondylitis at 4 years
For the first time for any biologic, data show almost 80 percent of ankylosing spondylitis (AS) patients on Cosentyx have no radiographic progression of the spine at 4 years These new data also confirm sustained improvement in signs and symptoms in almost 80 percent of patients, with a favorable and consistent safety profile Cosentyx, the only IL-17A inhibitor approved for AS, is a fully human, highly targeted biologic for first-line use in this
Life Sciences - Medicine/Pharmacology
03.11.2017
Reading our brain chemistry
Reading our brain chemistry
Researchers at EPFL have developed a new device and analysis method that let doctors measure the neurochemicals in a patient's brain. The  Microsystems Laboratory 4 (LMIS4)'s system involves collecting microdroplets of cerebral fluid and analyzing them to obtain chemical data that can help doctors diagnose and treat neurodegenerative diseases.
Environment/Sustainable Development - Life Sciences
03.11.2017
Mapping Functional Diversity of Forests with Remote Sensing
Mapping Functional Diversity of Forests with Remote Sensing
Ecological studies have demonstrated positive relationships between plant diversity and ecosystem functioning. Forests with higher functional diversity are generally more productive and stable over long timescales than less diverse forests. Diverse plant communities show increased resource use efficiency and utilization, enhanced ecosystem productivity and stability and can better cope with changing environmental conditions - an insurance effect of biodiversity.
Life Sciences - Environment/Sustainable Development
02.11.2017
UZH Anthropologists Describe Third Orangutan Species
Two species of Indonesian orangutans had previously been officially described and recognized - the Pongo abelii , living on the island of Sumatra, and the Pongo pygmeaeus , endemic to Borneo. In 1997, researchers at the Australian National University discovered an isolated population of orangutans in Batang Toru, a region within the three Tapanuli districts in North Sumatra.
Careers/Employment
02.11.2017
Confederation and the cantons adopt common strategy on exchanges and mobility
Bern, 02.11.2017 - The exchange and mobility strategy aims to make exchanges and mobility a natural part of education pathways, career trajectories and extracurricular activities.
Life Sciences - Medicine/Pharmacology
02.11.2017
How Caries-Causing Bacteria Can Survive in Dental Plaque
How Caries-Causing Bacteria Can Survive in Dental Plaque
Extracellular polysaccharides play a central role in the survival capabilities of caries-causing bacteria in dental plaque, report researchers from the University of Basel's Preventative Dentistry and Oral Microbiology Clinic and Department of Biomedical Engineering in the journal Plos One. Cariogenic bacteria live in biofilm and attack dental enamel by converting sugar and starch into acids that dissolve out calcium from the enamel.
Medicine/Pharmacology - Life Sciences
02.11.2017
Novartis and Amgen announce expanded collaboration with Banner Alzheimer’s Institute in pioneering prevention program
Parties to collaborate on a new Generation Study 2, assessing whether investigational drug CNP520 can prevent or delay the symptoms of Alzheimer's disease (AD)   Clinical trial is part of the Generation Program, which includes cognitively healthy people at genetic risk of developing AD   Generation Study 2 aims to include a broader high-risk population, as compared to the ongoing Generation Study 1        44 million people globally are e
Medicine/Pharmacology - Administration/Government
01.11.2017
Roche to present new data across a range of blood diseases at the American Society of Hematology (ASH) 2017 Annual Meeting
Roche to present new data across a range of blood diseases at the American Society of Hematology (ASH) 2017 Annual Meeting Further results from emicizumab phase III studies in people with haemophilia
Physics/Materials Science - Civil Engineering
01.11.2017
Research collaboration for sustainable
Research collaboration for sustainable
Buildings made of reusable components: that is the aim of a research collaboration between Empa and the University of Luxembourg.
Medicine/Pharmacology - Life Sciences
01.11.2017
Novartis presents data at ASH for patients with serious blood disorders like lymphoma, leukemia and sickle cell disease
Primary results of pivotal Kymriah TM Phase II JULIET study in relapsed/refractory DLBCL   Post-hoc sub-analysis of crizanlizumab (SEG101, formerly SelG1) SUSTAIN trial evaluating time to first sickl
Event - Environment/Sustainable Development
31.10.2017
Medicine/Pharmacology - Life Sciences
31.10.2017
Novartis submits application to FDA for KymriahTM (tisagenlecleucel) in adult patients with r/r DLBCL, seeking second indication for first-ever FDA approved CAR-T therapy
Novartis submits application to FDA for KymriahTM (tisagenlecleucel) in adult patients with r/r DLBCL, seeking second indication for first-ever FDA approved CAR-T therapy Submission based on updated
History/Archeology - Environment/Sustainable Development
31.10.2017
Three ways to preserve a Neolithic site
Three ways to preserve a Neolithic site
An EPFL study commissioned by the Canton of Bern has come up with three possible ways of protecting the Sutz-Lattrigen archaeological site, which offers a rare insight into the lives of pile dwellers.
Life Sciences - Medicine/Pharmacology
30.10.2017
Important Mechanism of Epigenetic Gene Regulation Identified
DNA contains the blueprint of an entire organism. Based on the information in this blueprint, every cell knows what it must become and what function it must perform. Throughout the entire lifespan of an organism, the genetic information has to be read correctly to ensure that genes are active at the right time and in the right cells.
Medicine/Pharmacology - Business/Economics
30.10.2017
Novartis announces the planned acquisition of Advanced Accelerator Applications to strengthen oncology portfolio
Novartis to acquire Advanced Accelerator Applications pending outcome of tender offer and works council consultation   Acquisition would add Lutathera , a first-in-class RadioLigand Therapy (RLT) app
Medicine/Pharmacology
30.10.2017
Novartis to present first of its kind evidence for Cosentyx on potential to maintain mobility in patients with AS and PsA
Long-term 4-year data in ankylosing spondylitis (AS) and 24-weeks data in psoriatic arthritis (PsA) to be presented at the 2017 ACR/ARHP Annual Meeting ,   Structural disease progression is a major c
Psychology
30.10.2017
Willingness to Take Risks - a Personality Trait
Willingness to Take Risks - a Personality Trait
People differ in their willingness to take risks. An individual's propensity for risk taking can also vary across domains. However, there is new evidence showing that there is also a general factor of individual risk preference, which remains stable over time - akin to the general Intelligence Quotient (IQ).
Astronomy - Physics/Materials Science
30.10.2017
Claude Nicollier, forever known as the first Swiss man in space
Claude Nicollier, forever known as the first Swiss man in space
Just 25 years ago, Vaud astronaut Claude Nicollier boarded the Space Shuttle Atlantis for the first of what would be four missions in space.
Medicine/Pharmacology - Life Sciences
28.10.2017
Novartis PARADIGMS data show children and adolescents with MS had an 82% lower relapse rate with Gilenya vs. interferon beta-1a
PARADIGMS data also show patients treated with Gilenya had significantly fewer new brain lesions vs.
Medicine/Pharmacology
27.10.2017
Life Sciences
27.10.2017
Advanced artificial limbs mapped in the brain
Advanced artificial limbs mapped in the brain
EPFL scientists from the Center for Neuroprosthetics have used functional MRI to show how the brain re-maps motor and sensory pathways following targeted motor and sensory reinnervation (TMSR), a neuroprosthetic approach where residual limb nerves are rerouted towards intact muscles and skin regions to control a robotic limb.
Medicine/Pharmacology - Business/Economics
27.10.2017
Sandoz proposed biosimilar pegfilgrastim accepted by EMA for regulatory review
Comprehensive data package demonstrates that Sandoz biosimilar pegfilgrastim matches the reference biologic in terms of safety, efficacy and quality Pegfilgrastim is a long-acting version of oncology
Medicine/Pharmacology - Life Sciences
26.10.2017
Bacteria Have a Sense of Touch
Bacteria Have a Sense of Touch
Although bacteria have no sensory organs in the classical sense, they are still masters in perceiving their environment. A research group at the University of Basel's Biozentrum has now discovered that bacteria not only respond to chemical signals, but also possess a sense of touch. In their recent publication in "Science", the researchers demonstrate how bacteria recognize surfaces and respond to this mechanical stimulus within seconds.
Medicine/Pharmacology - Life Sciences
25.10.2017
Novartis confirms leadership in multiple sclerosis (MS) with scientific advancements and new data presented at ECTRIMS
Full data from the pivotal Phase III PARADIGMS study of Gilenya (fingolimod) in pediatric MS will be presented for the first time   With 54 accepted abstracts, Novartis presence spans from new siponimod (BAF312) data in secondary progressive MS (SPMS) to innovative research on neurofilaments - a promising MS biomarker - Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at
Administration/Government - Astronomy
25.10.2017
Administrative enquiry opened
ETH Zurich is launching an administrative enquiry into allegations made in the Department of Physics.
Environment/Sustainable Development
25.10.2017
Developing a
Developing a "gravitational theory" for ecology
An important breakthrough by EPFL researchers could lead to the discovery of a set of general laws applicable to the environmental sciences. Is there a link between a given species' body mass and its abundance, or between the size of an ecosystem and its level of biodiversity? Ecologists often find that similar relationships of this type exist in different ecosystems.
Physics/Materials Science - Chemistry
24.10.2017
Stress test passed
Stress test passed
With a technology developed at the Paul Scherrer Institute PSI, around 60 percent more biogas can be produced from bio-waste than with conventional methods. But can it stand the test in practice as well? A 1,000-hour test at the Werdhölzli biowaste digestion and wastewater treatment plant in Zurich was able to answer this question with a clear yes.
Agronomy/Food Science - Environment/Sustainable Development
24.10.2017
Medicine/Pharmacology - Environment/Sustainable Development
24.10.2017
Tracking a parasite that's ravaging fish
Tracking a parasite that's ravaging fish
In Switzerland - not to mention the rest of Europe and the United States - freshwater fish are falling victim to a deadly disease that is rampant in the summer and dormant in the winter. It is caused by a parasite that thrives in rivers and attacks salmonid fish in particular. Researchers from EPFL, EAWAG and FIWI have come up with a mathematical model for predicting outbreaks as part of a three-year joint research program.
Business/Economics - Medicine/Pharmacology
24.10.2017
Novartis delivered growth on top and bottom line in all divisions in Q3
Net sales grew 2% (cc , +2% USD), with growth in all divisions: Cosentyx (USD 556 million, +83% cc) showed strong growth across all indications Entresto (USD 128 million, +138% cc) grew driven by imp
Life Sciences
24.10.2017
High-Speed Locomotion Neurons Found in the Brainstem
High-Speed Locomotion Neurons Found in the Brainstem
A clearly defined subpopulation of neurons in the brainstem is essential to execute locomotion at high speeds. Interestingly, these high-speed neurons are intermingled with others that can elicit immediate stopping. How defined groups of brainstem neurons can regulate important aspects of full motor programs, reports a study by researchers of the Biozentrum at the University of Basel and the Friedrich Miescher Institute for Biomedical Research (FMI).
Business/Economics - Environment/Sustainable Development
23.10.2017
First step towards climate-aligned financial flows
Bern, 23.10.2017 - In the context of the Paris Agreement, Swiss pension funds and insurance companies were invited by the Federal Office for the Environment FOEN and the State Secretariat for International Financial SIF to test the climate compatibility of their portfolios.
Civil Engineering - Social Sciences
23.10.2017
An app for rating public transport in real time
An app for rating public transport in real time
EPFL researchers have developed a smartphone app for passengers to evaluate their experience in real time and view other users' ratings.
Medicine/Pharmacology - Administration/Government
23.10.2017
Novartis combination adjuvant therapy Tafinlar + Mekinist receives FDA Breakthrough Therapy Designation for stage III BRAF V600 mutation-positive melanoma patients
Novartis combination adjuvant therapy Tafinlar + Mekinist receives FDA Breakthrough Therapy Designation for stage III BRAF V600 mutation-positive melanoma patients Breakthrough Therapy Designation ba